ALPPS for primary and metastatic liver cancer: the results of single-center study

Abstract

Background: The main goal was to assess safety and outcomes of ALPPS procedure and find the optimal compromise between dropout and mortality risk, using our initial single-center experience Methods: 20 patients who have underwent ALPPS resection at the Abdominal Oncology Department from Jan 2012 to Jun 2016 were retrospectively analyzed. Multivariate logistic regression analysis was performed to identify independent risk factors for severe complications, mortality and volume growth of the FLR Results: Mean age was 59,1±6,3(49 -72)years. Indications for surgical resection were CRLM in 80% and HCC in 20% cases. 1 patient had salvage ALPPS after failed PVL. Patients were operated for 2.8±1.6 metastases, the largest was 64.6±18.8 mm.The increase in FLR between the 2 steps was 95.3±53.6% (range: 13-164%, p<0.001).The average time between steps of the procedure was 9.4±1.4 days. Severe complications including mortalities (Clavien-Dindo≥IIIb) occurred in 6,7 and 9,1% of patients after ALPPS-1 and 2 resp. Follow-up mediana was 20 mo. Mean OS rate was 26,1 [22,5-29,6]mo. Mean DFS rate 24,1 [19,6-28,5]mo.Primary liver cancer, age, histologic changes of liver parenchyma, led to morbidity and mortality rate Conclusion: ALPPS should be reserved to a small proportion of patients, the young ones with very small future liver remnant, with the low rate of liver function reserve or experiencing inadequate hypertrophy after portal vein occlusion. For these patients ALPPS could still offer a benefit, being the only chance of resectability